Gossamer Bio to Participate in Upcoming Investor Conferences
News > Health News
Audio By Carbonatix
1:01 PM on Monday, November 24
The Associated Press
SAN DIEGO--(BUSINESS WIRE)--Nov 24, 2025--
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in December.
Piper Sandler 37 th Annual Healthcare Conference
Date / Time: | December 2 nd, at 9:00 AM ET |
Format: | Presentation & 1x1’s |
Location: | New York, NY |
Oppenheimer Movers in Rare Disease Summit
Date / Time: | December 11 th, at 9:00 AM ET |
Format: | Panel & 1x1’s |
Location: | New York, NY |
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251124688603/en/
CONTACT: For Investors and Media
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Gossamer Bio, Inc.
Copyright Business Wire 2025.
PUB: 11/24/2025 04:01 PM/DISC: 11/24/2025 04:01 PM
http://www.businesswire.com/news/home/20251124688603/en
